Spyre Therapeutics Inc., a clinical-stage biotechnology company, announced on June 6, 2025, that its independent Compensation Committee has approved the grant of stock options to three non-executive employees. The inducement awards, granted under the company's 2018 Equity Inducement Plan, allow for the purchase of 50,200 shares of common stock at an exercise price of $15.40 per share, consistent with the closing price on June 2, 2025. These options come with a 10-year term and vest over a four-year period, beginning with one-fourth of the shares after the first year of employment, followed by monthly vesting of one-forty-eighth of the shares. These terms are contingent upon continuous service with Spyre.